Tue. 27 Feb 2024, 7:45am ET
Benzinga
Earnings, News
Verve Therapeutics (NASDAQ:VERV) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.82) by 15.85 percent. This is a 2.99 percent decrease over losses of $(0.67) per share from the same period last year. The company reported quarterly sales of $5.14 million which beat the analyst consensus estimate of $1.17 million by 339.57 percent. This is a 408.20 percent increase over sales of $1.01 million the same period last year.